Lung Cancer | Specialty

Case Studies Showcase Recent Advances in Nonsquamous, Squamous NSCLC

August 23rd 2019

Practice-changing phase III trials including KEYNOTE-189, KEYNOTE-407, REVEL, and IMpower131, among several others, are laying the groundwork for how to treat patients with non–small cell lung cancer, specifically on an individualized basis.

Osimertinib Spearheads Progress in EGFR-Mutant NSCLC

August 20th 2019

Suresh A. Ramalingam, MD, discusses recent updates in EGFR-mutant non–small cell lung cancer and the next steps for osimertinib and other agents in this patient population.

Lurbinectedin NDA Anticipated in Small Cell Lung Cancer

August 19th 2019

A new drug application will be submitted to the FDA under accelerated approval status for lurbinectedin monotherapy for the second-line treatment of patients with small cell lung cancer, according to PharmaMar, the developer of the marine-derived agent.

Broader NGS Use in Oncology Hinges on Payers, Access, and Education

August 16th 2019

Using up-front, broadpanel genomic tests that include hundreds of genes can save money and, in some cases, improve outcomes compared with other diagnostic approaches, especially in lung cancer but also increasingly in breast, colorectal, skin, and other cancers.

Olaparib Combo Shows Promise in Small Cell Lung Cancer

August 16th 2019

Combining the PARP inhibitor olaparib (Lynparza) with temozolomide (Temodar) led to an overall response rate of 41.7% in patients with relapsed small cell lung cancer.

FDA Approves Entrectinib for NTRK+ Tumors and ROS1+ NSCLC

August 16th 2019

The FDA has granted an accelerated approval to entrectinib for the treatment of adult and pediatric patients ≥12 years of age with solid tumors that harbor a NTRK fusion, and has also approved the agent for the treatment of adults with ROS1-positive, metastatic non–small cell lung cancer.

Arsenal of Targeted Therapies Slated to Expand in NSCLC

August 15th 2019

Badi El-Osta, MD, discusses the targeted agents that are showing the most promise for patients with non–small cell lung cancer who have rare alterations and variants.

Rapid Advances in ALK+ and ROS1+ NSCLC Bring Forth New Challenges

August 13th 2019

Conor E. Steuer, MD, discusses emerging agents in the treatment of patients with ALK- or ROS1-positive non–small cell lung cancer and the sequencing challenges that have resulted in the space.

Osimertinib Improves Survival in Frontline EGFR+ NSCLC

August 9th 2019

Frontline osimertinib significantly improved overall survival compared with erlotinib or gefitinib in patients with EGFR-positive local advanced or metastatic non–small cell lung cancer, according to results from the phase III FLAURA trial.

Trial Data Validate Value of Lung Cancer Screening

August 8th 2019

Taofeek Owonikoko, MD, PhD, MSCR, discusses the results of the NLST and NELSON trials and the next steps that need to be addressed with lung cancer screening.

Lurbinectedin Study Shows Single-Agent Potential in Second-Line Small Cell Lung Cancer

August 7th 2019

Anna F. Farago, MD, PhD, discusses the second-line data with lurbinectedin and its potential impact on the small cell lung cancer field.

Biomarkers May Indicate Eligibility for PARP Inhibitors in Lung Cancer

August 5th 2019

Jonathan Riess, MD, MS, discusses ongoing research with PARP inhibitors in lung cancer and potential biomarkers for this class of agents.

Experts Discuss Highly Anticipated Study Results Across Tumor Types

August 5th 2019

OncLive interviewed experts at the State of the Science Summits in July 2019 on highly anticipated clinical trial results across tumor types.

Dr. Goldberg on Immune/Targeted Therapy Combos in Oncogene-Driven Lung Cancer

August 3rd 2019

Sarah B. Goldberg, MD, MPH, discusses the combination of immunotherapy and targeted therapy for the treatment of patients with oncogene-driven lung cancer.

Sequential Afatinib and Osimertinib Shows Sustained Real-World OS Benefit in EGFR+ NSCLC

August 2nd 2019

Treatment with afatinib (Gilotrif) followed by osimertinib (Tagrisso) led to a median overall survival of 41.3 months and a 2-year OS rate of 80% in patients with EGFR T790M-positive non–small cell lung cancer in a real-world setting.

NY-ESO-1 Gains Momentum as a Therapeutic Target

August 2nd 2019

As the immunotherapy research field grows, NY-ESO-1 is emerging as a high-priority target for cancer vaccine development and adoptive T-cell therapies.

Dr. Shaw on Sequencing Strategies in ALK-Positive NSCLC

August 2nd 2019

Alice T. Shaw, MD, PhD, associate professor of medicine at Harvard Medical School, director of Thoracic Oncology and Paula O’Keefe Endowed Chair in Thoracic Oncology at Massachusetts General Hospital, discusses sequencing strategies in ALK-positive non–small cell lung cancer (NSCLC).

Leading Oncologist Highlights Key Lung Cancer Advances

August 1st 2019

Konstantinos Arnaoutakis, MD, discusses pivotal updates in stage III disease, immunotherapy combinations in advanced non–small cell lung cancer, and advances in EGFR- and ALK-mutated lung cancer.

Novel Therapies for BRAF+ Colorectal Cancer

July 31st 2019

Treating BRAF+ Colorectal Cancer

July 31st 2019